Europe
Previously, Toujeo was approved only for adults aged 18 years and older.
iTeos Therapeutics SA announced that Michel Detheux, Ph.D., President and Chief Executive Officer, will present at the upcoming Piper Jaffray 31st Annual Healthcare Conference on Tuesday, December 3, 2019 at 10:50 a.m.
Data Safety Monitoring Board (DSMB) recommends the continuation of the RESOLVE-IT clinical trial without any modifications, based on the pre-planned review of safety data
Myovant Sciences to Present at the Evercore ISI 2nd Annual HealthCONx Conference on December 3, 2019
Myovant Sciences announced that Lynn Seely, M.D., Myovant’s President and CEO, will present at the Evercore ISI 2nd Annual HealthCONx Conference on Tuesday, December 3, 2019 at 10:35 a.m. Eastern Time in Boston, MA.
Galapagos NV announces a share capital increase arising from warrant exercises.
Kiadis Pharma N.V., a clinical stage biopharmaceutical company, announces that Kiadis will participate in the 2019 Piper Jaffray 31st Annual Healthcare Conference.
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers.
On 5 November 2019, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 and the Commission Delegated Regulation 2016/1052 of 8 March 2016.
IMVT-1401, a fully human anti-FcRn antibody designed to be administered via subcutaneous injection, is the only anti-FcRn antibody known to be in clinical development for the treatment of GO
Avadel Pharmaceuticals plc announced that it has achieved its patient enrollment target of 205 patients in the REST-ON Phase 3 clinical trial for its once-nightly sodium oxybate, FT218.
PRESS RELEASES